DelSiTech develops its own drug products by combining its silica-based drug delivery technology platform with known active substances to produce supergeneric/505(b)(2) products with superior characteristics over the original brand product.
Supergeneric/505(b)(2) drug development provides a low-risk alternative to traditional new chemical entity development in the pharmaceutical industry. With superior characteristics in comparison to the original brand product, supergeneric drug products can generate a significant cash-flow in a much shorter timeframe.
DelSiTech is developing in-house supergeneric/505(b)(2) products to the point at which the preliminary proof-of-concept has been demonstrated in clinical studies. This is followed by global licensing of the product to industry partner(s).
In House Programs
| Product candidate | Indication | Research | Preclinical | Clinical |
|---|
DelSiTech’s lead internal pipeline product, 1308, addresses a significant unmet medical need in infectious diseases
- First-in- class supergeneric/505(b)(2) drug candidate.
- Targets a significant unmet medical & market need in Chronic Hepatitis B
- 1308 is based on the most effective active antiviral compound in the indication, entecavir. The oral product, Baraclude, was approved in 2005 and is now off patent in all the major markets.
- 1308 is a 3 month injectable subcutaneous depot product which will significantly address the issue of non-adherence in patients
DelSiTech´s first topical ophthalmology product, DST2105, utilizes Silica Matrix technology for relieving dry eye symptoms.
- Represents a first-in-class long-acting artificial tear treatment, classified as a medical device.
- A single drop administered to cul-de-sac to provide relieve throughout the day
Partnered Programs
| Product candidate | Indication | Research | Preclinical | Clinical |
|---|
Development of long-acting controlled formulations of human immunodeficiency virus (HIV) anti-retrovirals supported by a grant from the Bill & Melinda Gates Foundation.
- The products developed are long acting injectable depots utilizing Silica Matrix technology.
- Targets a significant unmet global health need for HIV prevention.
Development of long-acting controlled formulations of contraceptives supported by a grant from the Bill & Melinda Gates Foundation.
- The products developed are long acting injectable depots utilizing Silica Matrix technology.
- Targets a significant global health need and new options for contraception.
Collaboration agreement with Solani Therapeutics to develop a sustained release product of Meloxicam for animal health.
- In ST15C, DelSiTech’s silica technology is used to address the difficulties in oral drug administration in cats
- Targets post-operative pain management in cats
- Releases meloxicam for 3 to 5 days after a single subcutaneous injection
Collaboration agreement with Visus Therapeutics to develop long-acting controlled release therapies in ophthalmology
- Silica Matrix technology is used to address the significant need for more durable treatments.